Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Arthritis model</td><td align="center">Species (strain)</td><td align="center">Maximum inhibition</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Adjuvant arthritis, lipoidal amine (AIA-LA)</td><td align="center">Rat (Lewis)</td><td align="center">20–30%</td></tr><tr><td align="left">Adjuvant arthritis, <i>Mycobacterium</i> (AIA-Myc)</td><td align="center">Rat (Lewis)</td><td align="center">30–60%</td></tr><tr><td align="left">Collagen-induced arthritis (CIA)</td><td align="center">Rat (DA)</td><td align="center">~25%</td></tr><tr><td align="left">Collagen-induced arthritis (CIA)</td><td align="center">Rat (Lewis)</td><td align="center">90–100%</td></tr><tr><td align="left">Streptococcal cell wall arthritis (SCW)</td><td align="center">Rat (Lewis)</td><td align="center">90–100%</td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left">Collagen-induced arthritis (CIA)</td><td align="center">Mouse (DBA/1)</td><td align="center">90–100%</td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>Treatment regimen: recombinant human interleukin-1 receptor antagonist (IL-1ra), infused at 5 mg/kg/hr for 7 days beginning at disease onset by subcutaneous osmotic minipump.<br/></td></tr></table>

Antiarthritic efficacy varies among different rodent models of immune-mediated arthritis.

BioMed Research International

tab3

Table 3

Table 3: Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy 